US$ 28.72
when were glp 1 drugs approved History of glucagon-like peptide-1 receptor agonists A Brief History of GLP-1
Description
Building on these results, a phase 1b trial in individuals with T2D further evaluated the safety, pharmacokinetics, and pharmacodynamics of once-weekly retatrutide over 12 weeks [43]

Retatrutide: A Triple Agonist with Unprecedented Efficacy Retatrutide (LY3437943) is a novel triple incretin agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

Texas Heart Institute Journal

The researchers noted, however, that the concentration of elenolic acid in olive oil is low, meaning the benefits seen in this study would likely require concentrated supplementation rather than dietary olive oil alone

doi: 10.1210/jcem.86.5.7463 [DOI] [PubMed] [Google Scholar] 197
It blocks the secretion of glucagon, which also helps to regulate your blood sugar levels when necessary by preventing more glucose from entering your bloodstream
